[Current status of targeted therapy for anaplastic lymphoma kinase in non-small cell lung cancer]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Anaplastic lymphoma kinase (ALK) gene rearrangements are found in 3%-5% of non-small cell lung cancer (NSCLC) cases.
• Crizotinib, a first-in-class ALK tyrosine kinase inhibitor, represents a personalized medicine advance for ALK-positive NSCLC.
• While effective, acquired resistance to crizotinib limits long-term outcomes in most patients.

Purpose of the Study:

• To review current knowledge on ALK fusion genes in NSCLC.
• To summarize treatment advances for ALK-rearranged NSCLC.
• To highlight novel therapeutic approaches and ongoing clinical trials.

Main Methods:

• Literature review of studies on ALK rearrangements in NSCLC.
• Analysis of clinical trial data for ALK inhibitors.
• Synthesis of information on resistance mechanisms and emerging therapies.

Main Results:

• Crizotinib demonstrated superiority over chemotherapy in previously treated ALK-positive NSCLC patients, showing durable responses and good tolerance.
• Most patients eventually develop acquired resistance to crizotinib, necessitating alternative treatment strategies.
• Second-generation ALK inhibitors (e.g., LDK378, CH5424802, AP26113) and heat shock protein 90 inhibitors are under clinical evaluation.

Conclusions:

• ALK rearrangements are a targetable driver in a subset of NSCLC.
• While crizotinib is an effective first-line treatment, acquired resistance is a significant clinical challenge.
• Ongoing research into novel ALK inhibitors and combination therapies holds promise for improving outcomes in ALK-positive NSCLC.